抗癌治疗后女性癌症幸存者AMH纵向轨迹的荟萃整合
该研究系统检索多个数据库,整合纵向研究,量化女性癌症患者抗癌治疗后AMH变化并模拟轨迹。乳腺癌12个月AMH降低76.4%,淋巴瘤ABVD方案降低21.1%、非ABVD方案降低90.1%,甲状腺癌放射性碘治疗降低57.9%,儿童及AYA混合癌降低63.1%;保留卵巢功能者长期AMH轨迹与同龄健康对照相似。
要点
- 乳腺癌治疗12个月AMH降低76.4%(95%CI -93.5至-55.7)。
- 淋巴瘤非ABVD方案AMH降低90.1%,ABVD方案降低21.1%。
- 保留卵巢功能者长期AMH下降与同龄健康对照相似。
核心结论
- 抗癌治疗后AMH在6至12-24个月间普遍回升,幸存者长期AMH下降与同龄对照相似。
研究设计与样本
- 系统检索CENTRAL、MEDLINE、Google Scholar、Embase和MedRxiv至2026年3月19日,纳入报告治疗前后或特定时间点AMH的女性癌症患者纵向研究。
- 采用JBI工具评估偏倚风险,GRADE评估证据确定性,在GraphPad Prism v10.6中分析。
主要发现
- 乳腺癌(中位年龄37.8岁,n=2259)12个月AMH降低76.4%(95%CI -93.5至-55.7;24项研究;GRADE中等)。
- 淋巴瘤ABVD方案(中位年龄24岁,n=146)12个月AMH降低21.1%(95%CI -81.6至+14.8;4项研究;GRADE低),非ABVD方案(中位年龄26.3岁,n=188)降低90.1%(95%CI -96.1至-68.3;6项研究;GRADE中等)。
- 甲状腺癌放射性碘治疗(中位年龄32.5岁,n=181)12个月AMH降低57.9%(95%CI -65.2至-36.4;4项研究;GRADE高)。
- 儿童及AYA混合癌(中位年龄9岁,n=176)12个月AMH降低63.1%(95%CI 64.3-61.9;4项研究;GRADE极低)。
- 保留卵巢功能的成人和儿童幸存者AMH轨迹相对稳定,与同龄健康对照高度一致。
关键数值与推荐
- 乳腺癌12个月AMH降低76.4%(95%CI -93.5至-55.7),证据确定性中等。
- 淋巴瘤ABVD方案12个月AMH降低21.1%(95%CI -81.6至+14.8),非ABVD方案降低90.1%(95%CI -96.1至-68.3)。
- 甲状腺癌放射性碘治疗12个月AMH降低57.9%(95%CI -65.2至-36.4),证据确定性高。
- 儿童及AYA混合癌12个月AMH降低63.1%(95%CI 64.3-61.9),证据确定性极低。
临床怎么用
- 可利用上述AMH变化估计对不同癌种及治疗方案患者进行卵巢功能咨询和生育力保护决策。
- 治疗后6至24个月AMH可能回升,解读时应结合时间点并与同龄健康对照比较。
局限性
- 长期卵巢储备数据仍有限,部分癌种和方案研究数量少、证据确定性低至极低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-Müllerian hormone (AMH) is widely used to assess gonadotoxicity related to anti-cancer treatments and to measure ovarian function in cancer survivors. The extent of AMH decline across malignancies and treatment regimens and the degree of subsequent recovery have not been systematically quantified. OBJECTIVE AND RATIONALE: The primary objective of this review was to quantify the change in AMH following cancer treatment and to model longitudinal AMH trajectories in survivors. The secondary objective was to compare AMH trajectories in cancer survivors with those of age-matched non-cancer controls. Data on long-term ovarian reserve after cancer treatment remain limited. This study integrates recent evidence and age-matched control data to better distinguish treatment-related AMH decline from normal reproductive ageing. SEARCH METHODS: A systematic search was performed across CENTRAL, MEDLINE, Google Scholar, Embase, and MedRxiv from inception until 24 January 2024, with an updated search on 19 March 2026. Both MEDLINE and Embase were searched via the Ovid platform, whilst Emtree index terms were used for EMBASE. The search strategy combined both index terms and free-text terms: (gonadotoxicity OR premature menopause OR premature ovarian insufficiency (POI) OR premature ovarian failure (POF)) AND (AMH OR Antimullerian* OR Anti-Mullerian) AND cancer. Studies were included if they involved female cancer patients of any age, including paediatric, adolescent and young adult (AYA), and adult populations, who received chemotherapy and who reported either pre- and post-treatment AMH levels or AMH measurements at defined time points after treatment. Studies were excluded if they did not report quantitative AMH data, involved male patients or non-human subjects, or included studies unrelated to cancer treatment-induced gonadotoxicity. The primary outcome was percentage change in AMH from baseline to 12 and 24 months from the end of treatment. Secondary outcomes included long-term AMH trajectories in adult and paediatric cancer survivors compared to the age-related decline in healthy controls. Risk of bias was assessed using the Joanna Briggs Institute (JBI) study-design-specific critical appraisal tools, and certainty of evidence was evaluated using GRADE. Analyses were performed in GraphPad Prism v10.6. OUTCOMES: Across all four cohorts (breast, lymphoma, thyroid, and paediatric/AYA mixed cancers), AMH levels were higher at 12 and 24 months compared with 6 months from the end of treatment. With breast cancer (median age 37.8 years, n = 2259), AMH was reduced by 76.4% at 12 months (95% CI: -93.5 to -55.7; 24 studies; GRADE: moderate-certainty evidence). With lymphoma, ABVD treatment regimens (median age 24 years, n = 146) were associated with a smaller reduction in AMH at 12 months (-21.1%; 95% CI: -81.6 to +14.8; four studies; GRADE: low-certainty evidence), whereas non-ABVD regimens (median age 26.3 years, n = 188) were associated with a larger reduction (-90.1%; 95% CI: -96.1 to -68.3; six studies; GRADE: moderate-certainty evidence). With thyroid cancer (median age 32.5 years, n = 181), radioactive iodine treatment was associated with a 57.9% reduction in AMH at 12 months (95% CI: -65.2 to -36.4; 4 studies; GRADE: high-certainty evidence). In the paediatric and AYA mixed cancers cohort (median age 9, n = 176), AMH was reduced by 63.1% at 12 months (95% CI: 64.3-61.9; four studies; GRADE: very low-certainty evidence). Among the adult and paediatric survivors who retained ovarian function, AMH trajectories remained relatively stable and closely aligned with age-matched healthy controls. WIDER IMPLICATIONS: AMH levels consistently improved between 6 and 12-24 months from the end of cancer treatment. We provide generalizable estimates of AMH trajectories in female survivors of both childhood and young adult cancer, indicating that their long-term AMH declines are similar to those of age-matched controls. REGISTRATION NUMBER: PROSPERO registration number: CRD420251000939.
引用
- Balachandren N, Kastora SL, Anderson RA, et al. Assessing the reproductive lifespan of female cancer survivors using AMH: a meta-synthesis of longitudinal studies. Hum Reprod Update. 2026. PMID: 42497321. doi:10.1093/humupd/dmag019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。